Natasha Leighl

Sep 10, 2024 | onclive.com | Natasha Leighl

Natasha B. Leighl, MD, BSc, MMSc, clinician investigator and member of the Cancer Clinical Research Unit (CCRU) at Princess Margaret Cancer Centre, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study (NCT05388669).

Jun 25, 2024 | onclive.com | Natasha Leighl

Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial Dr. Natasha Leighl presents the primary results of the phase 3, randomized controlled PALOMA-3 (NCT05388669) trial assessing the overall survival and non-inferiority of subcutaneous amivantamab compared to intravenous...

Jun 10, 2024 | ascopubs.org | Natasha Leighl

Authors retain all rights in any data supplements associated with their articlesThe ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.

May 15, 2024 | nature.com | Umberto Malapelle |Natasha Leighl |Dov Hershkovitz

AbstractNon-small cell lung cancer is a heterogeneous disease and molecular characterisation plays an important role in its clinical management. Next-generation sequencing-based panel testing enables many molecular alterations to be interrogated simultaneously, allowing for comprehensive identification of actionable oncogenic drivers (and co-mutations) and appropriate matching of patients with targeted therapies.

Apr 29, 2024 | cmaj.ca | William Phillips |Natasha Leighl |Normand Blais |Paul Wheatley-Price

KEY POINTSTargeted cancer therapies are a group of oral medications directed at tumours harbouring specific driver mutations that occur in a subset of patients with cancer. Around one-third to one-half of patients with advanced non–small cell lung carcinoma may harbour an actionable mutation, which can be identified from molecular analysis of a biopsy or surgical specimen.